Picture of Celsion logo

CLSN — Celsion Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-17.64%
3m-52.01%
6m-75.97%
1yr-85.14%
Volume Change (%)
10d/3m-80.23%
Price vs... (%)
52w High-89.89%
50d MA-38.08%
200d MA-74.26%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-41.04%
Return on Equity-50.49%
Operating Margin-4735.27%

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Latest News & Insights for CLSN

Could Celsion (NAQ:CLSN) be a turtle trade? background image

Could Celsion (NAQ:CLSN) be a turtle trade?

Ever since the 1980s, when the now-infamous "Turtle Traders" beat the market with simple strategies based on breakouts to new high prices, momentum investing has been shown to be a very profitable strategy.  In fact, many academics now...

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Celsion EPS forecast chart

Profile Summary

Celsion Corporation is a fully integrated, clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments, including deoxyribonucleic acid (DNA)-based immunotherapies, vaccines and directed chemotherapies through clinical trials and eventual commercialization. The Company's product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, its heat-activated liposomal encapsulation of doxorubicin, under investigator-sponsored development for several cancer indications. It has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies and vaccines, and other anti-cancer DNA or ribonucleic acid (RNA) therapies. Both are synthetic, non-viral vectors with capability in nucleic acid cellular transfection. Its TheraPlas is a technology platform for the delivery of DNA and messenger RNA (mRNA) therapeutics via synthetic non-viral carriers.

Directors

Last Annual
December 31st, 2021
Last Interim
March 31st, 2022
Incorporated
May 17th, 2000
Public Since
October 27th, 1993
No. of Shareholders
54,000
No. of Employees
29
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
7,098,741

CLSN Share Price Performance

Upcoming Events for CLSN

Celsion Corp Annual Shareholders Meeting

Celsion Corp Annual Shareholders Meeting

Q2 2022 Celsion Corp Earnings Release

Q3 2022 Celsion Corp Earnings Release

Similar to CLSN

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of 9 Meters Biopharma logo

9 Meters Biopharma

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acer Therapeutics logo

Acer Therapeutics

us flag iconNASDAQ Capital Market

FAQ

Or unlock with your email

Or unlock with your email